Transcriptional antagonism by CDK8 inhibition improves therapeutic efficacy of MEK inhibitors

被引：0

作者：

Malone, Clare F. ^{[1
]}

Kim, Minjee ^{[1
]}

Alexe, Gabriela ^{[1
]}

Forman, Alexandra B. ^{[1
]}

Robichaud, Amanda ^{[1
]}

Conway, Amy Saur ^{[1
]}

Goodale, Amy ^{[2
]}

Hatcher, John M. ^{[1
]}

Gray, Nathanael S. ^{[3
]}

Piccioni, Federica ^{[2
]}

Stegmaier, Kimberly ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Broad Inst, Cambridge, MA USA

[3] Stanford Univ, Stanford, CA USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2010

引用

页数：2

共 50 条

[31] CDK8 IS A DEPENDENCY IN GROUP 3 MEDULLOBLASTOMA AND COMBINES WITH BET BROMODOMAIN INHIBITION
Terrones, Isabella
Jagana, Hawa
Hathaway, Matthew
Hemenway, John
Rajendran, Ashmitha
Conrad, Jay
Evans, Myron
NEURO-ONCOLOGY, 2024, 26
[32] Molecular modeling studies of novel naphthyridine and isoquinoline derivatives as CDK8 inhibitors
Li, Qunlin
Feng, Kairui
Liu, Jianxin
Ren, Yujie
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (17): : 6355 - 6369
[33] Targeting CDK8: A translatable therapeutic approach for fusion-positive aRMS
Zhang, Susu
Malone, Clare
Guedes, Brian
Engel, Kathleen
Just, Marissa
Ross, Kenneth
Fahs, Assil
Digiovanni, Giulia
Granum, Diyana
Bentley, Rex
Barbar, Leen
Cerda-Smith, Christian
Mendes, Elizabeth
Erdogan, Ozgun
Kovach, Alexander
Oristian, Kristianne
Zimmerman, Seth
Shern, Jack F.
Wood, Kris
Counter, Chris
Linardic, Corinne M.
Stegmaier, Kimberly
CANCER RESEARCH, 2024, 84 (06)
[34] CDK8 protein complex as a potential biomarker and therapeutic target in breast cancer
McDermott, M. S. J.
Gyorffy, B.
Chumanevich, A. A.
Kaza, V.
Porter, D. C.
Catroppo, J. F.
Chen, M.
Oliver, D.
Shtutman, M.
Roninson, I. B.
Broude, E. V.
CANCER RESEARCH, 2016, 76
[35] MERTK inhibition improves therapeutic efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Llopiz, Diana
Silva, Leyre
Ruiz, Marta
Castro-Alejos, Carla
Aparicio, Belen
Vegas, Lucia
Infante, Stefany
Santamaria, Eva
Sarobe, Pablo
ONCOIMMUNOLOGY, 2025, 14 (01):
[36] Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors
Zhang, Haochao
Jing, Liandong
Liu, Man
Goto, Masuo
Lai, Fangfang
Liu, Xiao
Sheng, Li
Yang, Yajun
Yang, Ying
Li, Yan
Chen, Xiaoguang
Lee, Kuo-Hsiung
Xiao, Zhiyan
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223
[37] Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore
Schiemann, Kai
Mallinger, Aurelie
Wienke, Dirk
Esdar, Christina
Poeschke, Oliver
Busch, Michael
Rohdich, Felix
Eccles, Suzanne A.
Schneider, Richard
Raynaud, Florence I.
Czodrowski, Paul
Musil, Djordje
Schwarz, Daniel
Urbahns, Klaus
Blagg, Julian
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (05) : 1443 - 1451
[38] Developing CDK8 inhibitors as tool compounds: A case study in lean decision making
Koehler, Michael
Bergeron, Philippe
Blackwood, Elizabeth
Bowman, Krista
Clark, Kevin
Kiefer, James
McCleland, Mark
Salphati, Laurent
Schmidt, Stephen
Wu, Jiansheng
Beresini, Maureen
Firestein, Ron
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[39] Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
Chen, Mengqian
Li, Jing
Liang, Jiaxin
Thompson, Zanshe S.
Kathrein, Katie
Broude, Eugenia, V
Roninson, Igor B.
CELLS, 2019, 8 (11)
[40] Novel CDK8 inhibitors with long residence time new opportunities for cancer treatment
Benningshof, Jorg
van Meurs, Pauline
Damen, Eddy
Veerman, Johan
Weber, Holger
Totzke, Frank
Ehlert, Jan
Schachtele, Christoph
Kubbutat, Michael
Mueller, Gerhard
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251

← 1 2 3 4 5 →